NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
January 17, 2006 • Volume 3 / Number 3 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article

New FDA Guidance Aims to Speed Early Drug Development

Last week, the Food and Drug Administration (FDA) released two new guidance documents and a final rule intended to streamline the early clinical development of new drugs and biologics for cancer and other diseases. The documents represent strategic actions that are part of the agency's Critical Path Initiative. The Critical Path is a blueprint for updating the technologies and tools needed to optimize the process of discovery, development, and delivery of medical products. These specific guidances address major barriers in the early development of new interventions, including testing small quantities of new agents prior to undertaking full-scale clinical trials and evaluating new investigational agents in humans before demonstrating their manufacturability.

The joint NCI-FDA Interagency Oncology Task Force (IOTF), which was established in 2003 to enhance and accelerate the overall process of developing new cancer interventions, has focused extensively on these issues as part of its work to improve the overall cancer drug development process.  Read more  

Director's Update

NCI Advisors Explore Future Research Investment Strategies

Last week, NCI leadership held an important retreat with members of the institute's primary advisory panels. This was the 3rd annual NCI Joint Boards Retreat, and together we grappled with how NCI programs can continue their pioneering innovative trajectory, given the current fiscal limitations facing biomedical research.

As the discussion at the retreat illustrated, the ongoing budget constraints will require difficult but creative choices. The retreat also reinforced for me, however, the resolve of staff and the community to take the necessary steps to ensure continued progress against cancer by accelerating the pace of discovery, development, and delivery.

The President recently signed the appropriations bill that provides funding for the Department of Health and Human Services (HHS) for fiscal year 2006. The bill includes $4.842 billion for NCI. However, after a government-wide 1 percent reduction, as well as adjustments made for recisions, assessments, and mandatory increases, NCI starts FY 2006 with fewer dollars than FY 2005, an amount that was already lower than the previous year.  Read more  


The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.